Cargando…
COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination
The incidence of COVID-19 infection in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is similar to that in the general population, but the mortality rate is much higher. COVID-19 vaccination is strongly recommended for PAH/CTEPH patient...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706780/ https://www.ncbi.nlm.nih.gov/pubmed/34960141 http://dx.doi.org/10.3390/vaccines9121395 |
_version_ | 1784622275257958400 |
---|---|
author | Wieteska-Miłek, Maria Szmit, Sebastian Florczyk, Michał Kuśmierczyk-Droszcz, Beata Ryczek, Robert Kurzyna, Marcin |
author_facet | Wieteska-Miłek, Maria Szmit, Sebastian Florczyk, Michał Kuśmierczyk-Droszcz, Beata Ryczek, Robert Kurzyna, Marcin |
author_sort | Wieteska-Miłek, Maria |
collection | PubMed |
description | The incidence of COVID-19 infection in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is similar to that in the general population, but the mortality rate is much higher. COVID-19 vaccination is strongly recommended for PAH/CTEPH patients. The aim of our cross-sectional study was to identify reasons why PAH/CTEPH patients refused vaccination against COVID-19. Moreover, we assessed the safety profile of approved COVID-19 vaccines in PAH/CTEPH patients. We examined 261 patients (164 PAH patients and 97CTEPH patients) with a median age of 60 (18–92) years, 62% of which were female. Sixty-one patients (23%) refused to be vaccinated. The main reason for unwillingness to be vaccinated was anxiety about adverse events (AEs, 61%). Age and fear of COVID-19 in the univariate analysis and age ≥60 years in the multivariate regression analysis were factors that impacted willingness to be vaccinated (OR = 2.5; p = 0.005). AEs were reported in 61% of vaccinated patients after the first dose and in 40.5% after the second dose (p = 0.01). The most common reported AEs were pain at the injection site (54.5%), fever (22%), fatigue (21%), myalgia (10.5%), and headache (10%). A lower percentage of AEs was reported in older patients (OR = 0.3; p = 0.001). The COVID-19 vaccines are safe for PAH/CTEPH patients. The results obtained in this study may encourage patients of these rare but severe cardio-pulmonary diseases to get vaccinated against COVID-19. |
format | Online Article Text |
id | pubmed-8706780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87067802021-12-25 COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination Wieteska-Miłek, Maria Szmit, Sebastian Florczyk, Michał Kuśmierczyk-Droszcz, Beata Ryczek, Robert Kurzyna, Marcin Vaccines (Basel) Article The incidence of COVID-19 infection in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is similar to that in the general population, but the mortality rate is much higher. COVID-19 vaccination is strongly recommended for PAH/CTEPH patients. The aim of our cross-sectional study was to identify reasons why PAH/CTEPH patients refused vaccination against COVID-19. Moreover, we assessed the safety profile of approved COVID-19 vaccines in PAH/CTEPH patients. We examined 261 patients (164 PAH patients and 97CTEPH patients) with a median age of 60 (18–92) years, 62% of which were female. Sixty-one patients (23%) refused to be vaccinated. The main reason for unwillingness to be vaccinated was anxiety about adverse events (AEs, 61%). Age and fear of COVID-19 in the univariate analysis and age ≥60 years in the multivariate regression analysis were factors that impacted willingness to be vaccinated (OR = 2.5; p = 0.005). AEs were reported in 61% of vaccinated patients after the first dose and in 40.5% after the second dose (p = 0.01). The most common reported AEs were pain at the injection site (54.5%), fever (22%), fatigue (21%), myalgia (10.5%), and headache (10%). A lower percentage of AEs was reported in older patients (OR = 0.3; p = 0.001). The COVID-19 vaccines are safe for PAH/CTEPH patients. The results obtained in this study may encourage patients of these rare but severe cardio-pulmonary diseases to get vaccinated against COVID-19. MDPI 2021-11-25 /pmc/articles/PMC8706780/ /pubmed/34960141 http://dx.doi.org/10.3390/vaccines9121395 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wieteska-Miłek, Maria Szmit, Sebastian Florczyk, Michał Kuśmierczyk-Droszcz, Beata Ryczek, Robert Kurzyna, Marcin COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination |
title | COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination |
title_full | COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination |
title_fullStr | COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination |
title_full_unstemmed | COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination |
title_short | COVID-19 Vaccination in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Safety Profile and Reasons for Opting against Vaccination |
title_sort | covid-19 vaccination in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: safety profile and reasons for opting against vaccination |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706780/ https://www.ncbi.nlm.nih.gov/pubmed/34960141 http://dx.doi.org/10.3390/vaccines9121395 |
work_keys_str_mv | AT wieteskamiłekmaria covid19vaccinationinpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionsafetyprofileandreasonsforoptingagainstvaccination AT szmitsebastian covid19vaccinationinpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionsafetyprofileandreasonsforoptingagainstvaccination AT florczykmichał covid19vaccinationinpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionsafetyprofileandreasonsforoptingagainstvaccination AT kusmierczykdroszczbeata covid19vaccinationinpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionsafetyprofileandreasonsforoptingagainstvaccination AT ryczekrobert covid19vaccinationinpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionsafetyprofileandreasonsforoptingagainstvaccination AT kurzynamarcin covid19vaccinationinpatientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmonaryhypertensionsafetyprofileandreasonsforoptingagainstvaccination |